DIL
ENGN icon

Deeter Investments LLP’s enGene Therapeutics ENGN Stock Holding History

Deeter Investments LLP’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$813K Buy
+90,000
New +$721K 0.17% 64

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Deeter Investments LLP's ENGN Position: Q4 2025 in Review

Deeter Investments LLP opened a new position in enGene Therapeutics (ENGN) in Q4 2025: 90,000 shares worth $813K. The stake represents 0.17% of the portfolio and ranks #64 among its holdings.

58 funds tracked by Wall St. Rank hold ENGN as of Q4 2025.

  • Deeter Investments LLP held 90,000 shares of enGene Therapeutics worth $813K as of Q4 2025.
  • enGene Therapeutics was a new Deeter Investments LLP position in Q4 2025.
  • enGene Therapeutics made up 0.17% of Deeter Investments LLP's portfolio in Q4 2025, its #64 holding.
  • 58 funds tracked by Wall St. Rank held enGene Therapeutics as of Q4 2025.

Based on Deeter Investments LLP's 13F filing for Q4 2025, filed 28 Aug 2026.